Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > Humabody® VH Platform Humabody® VH Platform Humabody® VH Platform Crescendo’s heavy-chain only Humabody molecules are generated by the Crescendo Mouse, a patent-protected transgenic mouse platform (Teng et al, New Biotechnology Paper). Humabody VHs are the smallest part of an antibody capable of specific antigen binding, about a tenth the size of a standard antibody. This small size enables superior tissue accumulation and penetration, which translates to better therapeutic index compared to conventional IgGs (Nessler et al, Cancer Research Paper). Crescendo’s Humabody VHs offer a range of delivery routes for administration such as IV, subcutaneous, topical, pulmonary, oral, and ocular. Crescendo is able to mine a broad spectrum of fully human VHs with different binding characteristics and broad epitope coverage against virtually any target. VH raised against different targets can be formatted with flexible linkers to generate multispecifc, multifunctional therapeutic molecules (Multibody® VH) with novel mechanisms of action that cannot be achieved with standard antibodies. Crescendo’s technology also enables modulation of half-life extension. Crescendo’s own pipeline is focused on immuno-oncology applications, however Crescendo is also able to partner in a number of technology applications and different disease areas. Crescendo has VHs available for a number of oncology and immuno-oncology targets. To find out more, please contact us. Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design